Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
Our Pipeline
Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
|
Investigational Therapy |
Platform |
Investigational Indication |
Phase |
||
|
Cabozantinib* |
|||||
|
Targeted therapy |
Metastatic castration-​resistant prostate cancer (JP) |
Phase 3 |
|||
|
Targeted therapy |
2L metastatic non-small cell lung cancer (JP) |
Phase 3 |
|||
|
Description: Tyrosine kinase inhibitor including MET/AXL/VEGFR Additional information: Cabozantinib is being developed in Japan in collaboration with Exelixis. |
|||||
|
Ixazomib* |
|||||
|
Proteasome inhibitor |
Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU) |
Phase 3 |
|||
|
Proteasome inhibitor |
Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN) |
Phase 3 |
|||
|
Description: Proteasome inhibitor |
|||||
|
Mobocertinib* |
|||||
|
Targeted therapy |
2L EGFR Exon20 insertion non-small cell lung cancer (CN) |
Filed |
|||
|
Targeted therapy |
2L EGFR Exon20 insertion non-small cell lung cancer (JP) |
Phase 3 |
|||
|
Targeted therapy |
1L EGFR Exon20 insertion non-small cell lung cancer |
Phase 3 |
|||
|
Description: Oral EGFR Exon20 tyrosine kinase inhibitor |
|||||
|
Ponatinib* |
|||||
|
Targeted therapy |
FL Ph+ acute lymphocytic leukemia (US) |
Phase 3 |
|||
|
Targeted therapy |
Pediatric Ph+ acute lymphoblastic leukemia |
Phase 1 |
|||
|
Description: BCR-ABL inhibitor Additional information: Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). |
|||||
|
Relugolix* (TAK-385) |
|||||
|
Small molecule |
Prostate cancer (JP, Asian countries) |
Phase 3 |
|||
|
Description: GnRH Antagonist Additional information: Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc. |
|||||
|
Niraparib* |
|||||
|
Targeted therapy |
Triple-negative breast cancer |
Phase 3 |
|||
|
Description: |
|||||
|
Modakafusp Alfa (TAK-573) |
|||||
|
I-O cold-to-hot |
Multiple myeloma |
Phase 1/2 |
|||
|
I-O cold-to-hot |
Solid tumors |
Phase 1/2 |
|||
|
Description: Immune targeting attenuated cytokine Additional information: Modakafusp alfa (TAK-573) was licensed from Teva Pharmaceuticals. |
|||||
|
Subasumstat (TAK-981) |
|||||
|
I-O cold-to-hot |
Solid tumors |
Phase 1/2 |
|||
|
I-O cold-to-hot |
Non-Hodgkin lymphoma |
Phase 1/2 |
|||
|
I-O cold-to-hot |
Multiple myeloma |
Phase 1/2 |
|||
|
Description: SUMOylation inhibitor |
|||||
|
TAK-007 |
|||||
|
I-O redirected immunity |
B-cell malignancies |
Phase 2 |
|||
|
Description: CD19 CAR NK Additional information: TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center. |
|||||
|
TAK-186 |
|||||
|
I-O redirected immunity |
Solid tumors |
Phase 1/2 |
|||
|
Description: EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy |
|||||
|
TAK-102 |
|||||
|
I-O redirected immunity |
Solid tumors |
Phase 1 |
|||
|
Description: GPC3 targeted CAR-T Additional information: TAK-102 was licensed from Noile-Immune Biotech. |
|||||
|
TAK-103 |
|||||
|
I-O redirected immunity |
Solid tumors |
Phase 1 |
|||
|
Description: Mesothelin targeted CAR-T Additional information: TAK-103 was licensed from Noile-Immune Biotech. |
|||||
|
TAK-500 |
|||||
|
I-O cold-to-hot |
Solid tumors |
Phase 1 |
|||
|
Description: Targeted STING agonist |
|||||
|
TAK-676 |
|||||
|
I-O cold-to-hot |
Solid tumors |
Phase 1 |
|||
|
Description: STING agonist |
|||||
|
TAK-940 |
|||||
|
I-O redirected immunity |
B-cell malignancies |
Phase 1 |
|||
|
Description: CD19-1XX CAR-T Additional information: TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center. |
|||||
|
TAK-280 |
|||||
|
I-O redirected immunity |
Solid tumors |
Phase 1/2 |
|||
|
Description: |
|||||
*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets
Explore More
Newsroom
Keep up on the latest Oncology news by visiting our newsroom
Partnership Strategy
We believe the best way to achieve our aspiration to cure cancer is by working together
R&D Approach
Decades of leadership in Oncology with a diverse and robust pipeline